These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15840686)

  • 1. Erythropoietin receptors: their role beyond erythropoiesis.
    Rossert J; Eckardt KU
    Nephrol Dial Transplant; 2005 Jun; 20(6):1025-8. PubMed ID: 15840686
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiology and function of the erythropoietin receptor.
    Yoshimura A; Misawa H
    Curr Opin Hematol; 1998 May; 5(3):171-6. PubMed ID: 9664155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of stat signals during red blood cell development.
    Watowich SS; Mikami A; Busche RA; Xie X; Pharr PN; Longmore GD
    J Interferon Cytokine Res; 2000 Dec; 20(12):1065-70. PubMed ID: 11152572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythropoietin: from the receptor to erythropoiesis stimulating agents].
    Rieu P
    Nephrol Ther; 2009 Sep; 5(5 Suppl):1-5. PubMed ID: 19761972
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.
    Sinclair AM; Todd MD; Forsythe K; Knox SJ; Elliott S; Begley CG
    Cancer; 2007 Aug; 110(3):477-88. PubMed ID: 17582631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.
    Socolovsky M; Nam H; Fleming MD; Haase VH; Brugnara C; Lodish HF
    Blood; 2001 Dec; 98(12):3261-73. PubMed ID: 11719363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erythropoiesis and signal transduction: basic and clinical aspects].
    Komatsu N
    Rinsho Ketsueki; 2001 May; 42(5):393-6. PubMed ID: 11452458
    [No Abstract]   [Full Text] [Related]  

  • 8. Corticosteroids and erythropoeitin-receptor agonists.
    McLachlan CS
    CMAJ; 2008 Jan; 178(1):66. PubMed ID: 18166738
    [No Abstract]   [Full Text] [Related]  

  • 9. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
    Sasak C
    Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents: development, detection and dangers.
    Franz SE
    Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model.
    Kitamura H; Isaka Y; Takabatake Y; Imamura R; Suzuki C; Takahara S; Imai E
    Nephrol Dial Transplant; 2008 May; 23(5):1521-8. PubMed ID: 18194980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss.
    Arroliga AC; Guntupalli KK; Beaver JS; Langholff W; Marino K; Kelly K
    Crit Care Med; 2009 Apr; 37(4):1299-307. PubMed ID: 19242343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia.
    Littlewood TJ; Schenkel B; Liss M
    Oncologist; 2005 May; 10(5):357-60. PubMed ID: 15851794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
    Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML
    Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
    Breiterman-White R
    Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.